Last reviewed · How we verify
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in Combination With Nab-Paclitaxel and carboplatin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC).
Details
| Lead sponsor | Tianjin Medical University Cancer Institute and Hospital |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | UNKNOWN |
| Enrolment | 420 |
| Start date | Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jun 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Triple Negative Breast Cancer
Interventions
- Camrelizumab
- Nab-Paclitaxel
- Carboplatin
Countries
China